Contents

Volume 82 Issue 6 | ARD June 2023

Editorial
727 Greetings from the editor 2023/2
J S Smolen

Reviews
M Kostopoulos, A Fanouriakis, G Botsaris, D T Boumpas
734 Site of invasion revisited: epigenetic drivers of joint destruction in RA
C Ospelt

Views on news
740 At the crossroads of inflammation and fibrosis: epiregulin
S O’Reilly

Recommendations
742 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
754 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Cortes, A Banke, P G Conaglen, W A Dilts, P Biesem, M-L Elentjes, G Cavall, M Visser, D T Boumpas, G Berinhasa, M Wahlen-Herlenius, J Rebekwinkle, M-I Frömmed, M K C. Kow, L Rönntllm, M A Versel, E M Vial

763 Instrument selection for the ASAS core outcome set for axial spondyloarthritis

778 Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force

Rheumatoid arthritis
799 Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage
T Li, C Ca, A Kraimer, O Sorela, M A Loa Ag释li, L Johansson, K Fordal, F Lindfors, M Yang, B Xu, Q Li, L Cheng, G Borenst, G Fernandez, A Kasilton, S Rantapää-Dahlqvst, I Gjerston, R Holmård

809 Immunogenic analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance

Psoriatic arthritis
820 Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries

More contents ▶

This article has been chosen by the Editor to be of special interest or importance and is freely available online.
This article has been made freely available online under the BMJ Journals open access scheme.
See http://authors.bmj.com/open-access/
Osteoarthritis

866 Increased risk of osteoarthritis in patients with atopic disease
M C Baker, K Sheth, R Lu, D Lu, E P von Kaeppelin, A Blatt, D T Felton, W H Robinson

873 Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect

Letters

881 BlyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept
S Gai, Z Hu, Y Chen, Y Chen, B Ming, R Gao, Z Li, C Ye, J Zhong, L Dong

883 Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases
e134 Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study' by Kaklamanos, P Karamichalos, P G Vlachoyiannopoulos, A G Tzioufas

e135 Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al

S Artahi, J H M Driessen, A M Burden, P C Soverein, J P van den Bergh, A Boonen

e136 Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?' by Roongta et al

V F A M Derksen, D van der Woude

e137 Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al

C Robinson, J D Reveille, K L Windroy, D Chi

e138 Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Rosenbaum et al

K L Hynch, M Schäfer, A Stringfeld, I Cormens, I Cossac, E F Matteo, S Lawson-Tovey, M Gianfrancesco, P C Robinson, J Vázalony, P M Machado

e139 Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

R M Flood, R Conway, C Kirby, D Gheza, D J Kane, R H Mullan

e140 Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al

R M Flood, R Conway, C Kirby, D Gheza, D J Kane, R H Mullan

e141 Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Cheng and Zhang

C Cheng, F Zhang

e142 Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang

Z Gong, F Zhang

e143 Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Gong and Zhang

S Artahi, J H M Driessen, A M Burden, P C Soverein, J P van den Bergh, A Boonen

e144 Correspondence on 'Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus' by Batu et al

C Adamicheva, G Berris

e145 Response to: 'Correspondence on 'Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus'' by Batu et al

P Gauckler, E I Bentac, A Kronbihler

e146 Correspondence on: 'What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern' by Hocevar et al

A Hocevar, A Ambrožič, M Tomšič

e147 Response to: 'Correspondence on 'What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern'' by Hocevar et al

P Gauckler, E I Bentac, A Kronbihler

e148 Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial' by de Wolff et al

L de Wolff, S Arends, G M Van Steen, A Vissink, F G M Koese, H Boonstra

e149 Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al

R Felten, J-E Cottenberg

e150 Correspondence on 'Warfarin use and risk of knee and hip replacements' by Cheng and Zhang

C Cheng, F Zhang

e151 Response to: 'Correspondence on 'Warfarin use and risk of knee and hip replacements'' by Cheng and Zhang

T Noëggi, C Pelsquin, P Ballal, C G Boer

e152 Paradoxical gastrointestinal effects of interleukin-17 blockers

P Mehta, A Lawrence, A Aggarwal